Wendy K Marsh1, Joyce T Bromberger2, Sybil L Crawford3, Katherine Leung4, Howard M Kravitz5, John F Randolph6, Hadine Joffe7, Claudio N Soares8. 1. Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA. 2. Departments of Epidemiology and Psychiatry, University of Pittsburgh, Pittsburgh, PA. 3. Division of Preventive and Behavioral Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA. 4. Department of Obstetrics and Gynecology, University of Massachusetts Medical School, Worcester, MA. 5. Department of Psychiatry and Department of Preventive Medicine, Rush University Medical Center, Chicago, IL. 6. Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI. 7. Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 8. Department of Psychiatry, Queen's University School of Medicine, Kingston, Ontario, Canada.
Abstract
OBJECTIVE: Depression risk increases during the menopausal transition (MT) and initial postmenopausal years-both times of significant fluctuations of estrogen. Research to date provides limited support for the hypothesis that estrogen fluctuations play a role in the greater susceptibility to midlife depression. Importantly, not all women report depressive symptoms during the MT, and recent reports suggest that duration of exposure to estradiol throughout the adult years may also play a role in vulnerability to depression. This study examines patterns of estrogen exposure during the reproductive years and risk of depression during the MT and early postmenopausal years. METHODS: A longitudinal, US community-based, multiethnic study of menopause. Data were collected at baseline and annually for 10 years, and included 1,306 regularly menstruating premenopausal women, aged 42 to 52 years at study entry. The main outcome was incidence of high level of depressive symptoms, Center for Epidemiological Studies Depression Scale (CES-D) score at least 16, in the MT and initial postmenopausal years, independent of premenopausal depression symptoms. Risk factors examined were duration of estrogen exposure (menarche to MT), duration of hormonal birth control use, pregnancies, and lactation. RESULTS: In a multivariate adjusted model, longer duration of estrogen exposure from menarche to MT onset was significantly associated with a reduced risk of depression (CES-D ≥16) during the MT and 10 years or less postmenopause (odds ratio 0.85, 95% confidence interval 0.78-0.92). Longer duration of birth control use was associated with a decreased risk of CES-D at least 16 (odds ratio 0.90, 95% confidence interval 0.83-0.98), but number of pregnancies or breastfeeding was not. CONCLUSIONS: Patterns of reproductive lifetime exposure to estrogen are associated with risk of high depressive symptoms during the MT and initial postmenopausal years; longer exposure to estrogen seemed protective.
OBJECTIVE:Depression risk increases during the menopausal transition (MT) and initial postmenopausal years-both times of significant fluctuations of estrogen. Research to date provides limited support for the hypothesis that estrogen fluctuations play a role in the greater susceptibility to midlife depression. Importantly, not all women report depressive symptoms during the MT, and recent reports suggest that duration of exposure to estradiol throughout the adult years may also play a role in vulnerability to depression. This study examines patterns of estrogen exposure during the reproductive years and risk of depression during the MT and early postmenopausal years. METHODS: A longitudinal, US community-based, multiethnic study of menopause. Data were collected at baseline and annually for 10 years, and included 1,306 regularly menstruating premenopausal women, aged 42 to 52 years at study entry. The main outcome was incidence of high level of depressive symptoms, Center for Epidemiological Studies Depression Scale (CES-D) score at least 16, in the MT and initial postmenopausal years, independent of premenopausal depression symptoms. Risk factors examined were duration of estrogen exposure (menarche to MT), duration of hormonal birth control use, pregnancies, and lactation. RESULTS: In a multivariate adjusted model, longer duration of estrogen exposure from menarche to MT onset was significantly associated with a reduced risk of depression (CES-D ≥16) during the MT and 10 years or less postmenopause (odds ratio 0.85, 95% confidence interval 0.78-0.92). Longer duration of birth control use was associated with a decreased risk of CES-D at least 16 (odds ratio 0.90, 95% confidence interval 0.83-0.98), but number of pregnancies or breastfeeding was not. CONCLUSIONS: Patterns of reproductive lifetime exposure to estrogen are associated with risk of high depressive symptoms during the MT and initial postmenopausal years; longer exposure to estrogen seemed protective.
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: Menopause Date: 2012-04 Impact factor: 2.953
Authors: Heather A Kenna; Molly Tartter; Scott S Hall; Amy A Lightbody; Quynh Nguyen; C Paula de los Angeles; Allan L Reiss; Natalie L Rasgon Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2013-09-03 Impact factor: 3.568
Authors: P J Schmidt; L Nieman; M A Danaceau; M B Tobin; C A Roca; J H Murphy; D R Rubinow Journal: Am J Obstet Gynecol Date: 2000-08 Impact factor: 8.661
Authors: Joel S Finkelstein; Sarah E Brockwell; Vinay Mehta; Gail A Greendale; MaryFran R Sowers; Bruce Ettinger; Joan C Lo; Janet M Johnston; Jane A Cauley; Michelle E Danielson; Robert M Neer Journal: J Clin Endocrinol Metab Date: 2007-12-26 Impact factor: 5.958
Authors: Elżbieta Grochans; Małgorzata Szkup; Artur Kotwas; Jacek Kopeć; Beata Karakiewicz; Anna Jurczak Journal: Int J Environ Res Public Health Date: 2018-04-10 Impact factor: 3.390